Healthcare Industry News:  M. D. Anderson Cancer Center 

Biopharmaceuticals Devices

 News Release - April 4, 2006

NCCN Introduces Venous Thromboembolic Disease Guidelines

JENKINTOWN, Pa.--(HSMN NewsFeed)--April 4, 2006--The National Comprehensive Cancer Network (NCCN) today announces the release of the new NCCN Venous Thromboembolic (VTE) Disease Guidelines. These guidelines outline the diagnosis, treatment and prevention of VTE--a potentially serious condition that occurs when a blood clot forms in the deep veins of the legs or in the pelvic veins. Cancer patients are especially at risk for VTE, which can result in serious complications like pulmonary embolism if not diagnosed and treated effectively. As a result, NCCN has included VTE as part of The NCCN Clinical Practice Guidelines in Oncology(TM), which are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are updated continually and are based upon evaluation of scientific data integrated with expert judgment.

"The interest in and concern about VTE has increased dramatically in the last few years. Physicians need a resource that outlines new and effective diagnostic techniques and therapeutic strategies not only for VTE, but also to prevent pulmonary embolism," said Lawrence D. Wagman, M.D., Chair of the VTE Panel and Director of the Liver Tumor Program at City of Hope Cancer Center. "The VTE Panel represents the united expertise of medical professionals, including hematologists, oncologists, pharmacologists and cardiologists. Together, we created this detailed guideline for physicians that helps them anticipate and treat VTE, a condition that many cancer patients are at risk for developing."

For more information about the VTE Guideline, please go to

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN member institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN member institutions are: City of Hope Cancer Center, Los Angeles, CA; Dana-Farber/Partners CancerCare, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Hospital & Clinics, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The University of Nebraska Medical Center, Omaha, NE; and The University of Texas M. D. Anderson Cancer Center, Houston, TX.

For more information, visit

Source: National Comprehensive Cancer Network

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.